Articles tagged with Tumor Cells
Researchers at UCLA Health Jonsson Comprehensive Cancer Center discovered that the protein IRF1 can both hinder and help the body's immune response to tumors, depending on which cells it is found in. The study suggests that targeting IRF1 could enhance cancer treatment effectiveness by boosting natural antitumor immunity.
Researchers identify key proteins and signaling pathways for personalized treatment, enabling early detection of aggressive tumors. The study provides a crucial resource for developing new therapies and tests to guide treatment.
Researchers at CeMM have identified a synthetic variant inspired by the Withanolides group that acts highly specifically against leukemia cells. The molecule disrupts the cholesterol metabolism of tumor cells.
Researchers created nanomicelles containing substances already approved for human use, which reduced inflammation in the tumor microenvironment and facilitated the action of the immune system. The treatment induced a reduction of over five times in tumor volume compared to untreated tumors.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.
A new study published in Nature Biomedical Engineering shows that targeted cancer treatment using antibody-displaying extracellular vesicles reduces tumour growth and improves survival in mice. The treatment has the potential to be used against other diseases and cancer types, offering a more effective and fewer side effects compared t...
Researchers found that blocking PI3K-beta makes glioblastoma cells more sensitive to temozolomide treatment, slowing down tumor growth. The study's findings could lead to new treatments for patients with chemotherapy-resistant glioblastoma.
Researchers identified EHF as a critical transcription factor in cholangiocarcinoma development through activation of GLI1 and CCL2. Targeted therapies targeting these pathways showed promise in inhibiting tumor growth and infiltration.
Glioblastoma cancer cells change their appearance and behavior to evade T-cell attack, rendering immunotherapy ineffective. Researchers found that these 'plastic' cells can also exhaust T-cells, making glioblastoma resistant to treatment.
Researchers have identified a novel protein FOXF1 that stabilizes blood vessels inside lung tumors, decreasing intertumoral hypoxia and preventing lung cancer metastases. Increasing levels of FOXF1 or FZD4 shows promise to improve therapeutic outcomes in lung cancer patients.
A microfluidic device separates single tumor cells, tumor cell clusters, and white blood cells from clinical pleural or abdominal effusions. The technology recovers over 97% of tumor cells and preserves 90% of vital tumor cell clusters.
A large trial enrolling nearly 2,800 patients from five countries has clarified the situation for patients with larger metastases. The study found that leaving most of the lymph nodes intact resulted in similar recurrence rates as completion axillary dissection, but with fewer arm-related complications.
Researchers at the University of Oklahoma have discovered how pancreatic cancer cells exploit an acidic environment to their advantage, finding ways to survive and grow. This knowledge is crucial for developing new therapeutic approaches to target the cancer.
Researchers developed an AI model to detect viable tumor cells in osteosarcoma patients, improving prognosis predictions. The model showed comparable detection performance to pathologists and reduced inter-assessor variability, enabling timely assessment.
Researchers unveil innovative strategies to overcome metabolic constraints in CAR-T cell therapy, aiming to boost its efficacy in treating solid tumors. Metabolic interventions targeting immunosuppressive metabolites, metabolite uptake, and mitochondrial metabolism are proposed to enhance anti-tumor activity.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
A UNIGE team has identified the mechanism of action of PARP inhibitors, used to treat breast and ovarian cancer. By blocking one activity while preserving another, these inhibitors can maintain toxic effects on cancer cells while sparing healthy cells.
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
A new nanocarrier has been developed that can selectively release drugs in cancer cells through controlled endosomal escape. The approach exploits the unique enzymatic activity of cancer cells, allowing for targeted delivery and reduced harm to healthy cells.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
A novel chemotherapy approach uses patient's own cells as Trojan horses to deliver targeted cancer-killing drugs to lung cancer cells. The method has shown promise in reducing tumor size and improving treatment efficacy with minimal collateral damage to healthy tissues.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
Researchers found that artepillin C interacts intensely with tumor cells, altering their fluidity and triggering autophagy. The study's results contribute to a deeper understanding of the substance's action mechanisms and provide insights for future research.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
A novel reporter cell experimental system enables the visualization of sequential changes during endothelial-mesenchymal transition (EndoMT) induced by transforming growth factor-β. Researchers identified CD40 as a potential partial EndoMT marker, which suppresses the transition from partial to full EndoMT.
Researchers discovered that immune cells called natural killer cells rapidly lose their functionality when entering solid tumours, adopting a dormant state. However, targeting the IL-15 pathway can restore NK cell activity and improve tumor control. This breakthrough could pave the way for new cancer treatments.
Researchers have developed a synergistic antitumor drug that activates calcium channels in tumor cells, leading to a deadly influx of calcium ions. The treatment involves using a bioactive agent to generate reactive oxygen species, which triggers the activation of calcium channels in both the outer membrane and endoplasmic reticulum.
A new cancer GPS method uses a water-soluble, luminescent europium complex to evaluate the malignancy grade of model glioma tumor cells without causing harm. The method measures changes in the lifetime of the complex's red-light emission, revealing differences in tumor activity and growth processes between different malignancy grades.
A team of researchers created a 3D bioprinted brain blood vessel model to investigate the impact of blood vessel curvature on metastatic cancer development. The model revealed that increased blood vessel curvature correlates with heightened cancer cell adherence and extravasation.
Researchers aim to improve glioma treatment with direct light therapy that targets cancer cells without harming healthy ones. The project will investigate the efficacy and safety of this approach, potentially leading to improved treatment outcomes.
A study by the University of Sheffield found that breast cancer cells take advantage of nutrients in the extracellular matrix when faced with nutrient starvation. The cells use an ingestion process called macropinocytosis to consume the matrix, breaking it down into energy-releasing substrates.
Breast cancer cells survive by consuming the extracellular matrix when nutrients are scarce. The process involves macropinocytosis and metabolic conversion of key amino acids to energy-releasing substrates. This mechanism could represent a novel therapeutic target.
A team of scientists has identified a previously unrecognized control point in DNA repair processes, which could lead to novel cancer therapies by inhibiting the repair of damaged cancer cells. The newly discovered GSE1-CoREST complex contains three enzymes that control DNA repair and may form the basis for improved cancer treatments.
Researchers at UMass Amherst have discovered that tumor cells outwit the body's immune system by incorporating cytoplasmic material into their own T cells. This 'mosquito effect' helps cancerous tumors evade the immune system, making it a promising area of study for developing more effective treatments.
A new MRI-based method uses CEST technology to detect water cycling across cellular membranes, providing a non-invasive way to assess tumor malignancy and treatment effectiveness. The technique sheds light on tumor phenotype and offers a promising tool for personalized cancer diagnosis and therapy.
Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...
Researchers have decoded the factor driving rapid growth of T cell lymphomas, revealing a 'sugar appetite' that triggers processes leading to tumor growth. The discovery provides new hope for treating aggressive cancer types, with existing medications potentially effective against these tumors.
A study by the University of the Basque Country uses game theory to establish that tumours with less cellular heterogeneity are more aggressive. The work suggests a fresh theoretical approach for new therapeutic strategies, focusing on preserving high intratumour heterogeneity.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
Researchers found that tumor-resident T-cell receptor sequences showed high complementarity with the cancer testis antigen DDX53, suggesting an immune response that selects for DDX53-negative cells. This association was correlated with worse disease-free survival rates, highlighting a potential early esophageal cancer antigen.
Research reveals chromatin's role in preventing DNA-RNA hybrid formation, which causes genomic instability and cancer. DNA-RNA hybrids are a risk factor in tumour development, suggesting potential use as an indicator of carcinogenic risk.
Researchers developed nanoparticles to transport Gemcitabine directly into tumors, increasing efficacy and sparing healthy cells. The approach shows potential to treat pancreatic carcinomas more accurately and with reduced side effects.
Researchers are exploring new ways to fight metastasis, including the use of bacteria to activate a defensive response against cancer. Stress and changes in circadian rhythms have also been linked to metastasis, suggesting that these factors may be targets for prevention or treatment.
Researchers at Purdue University have developed a novel cancer immunotherapy compound that targets the enzyme TC-PTP, found in both cancer cells and T cells. Deleting this enzyme promotes antigen presentation, alerting the immune system to tumor cells, while stimulating T-cell activation enhances their ability to fight and destroy tumors.
A new AI method combines satellite imaging and ecological analysis techniques to interpret large amounts of data from tumor tissue, providing insights into how cancer works. This approach aims to tailor cancer treatments to individual needs and avoid unnecessary side effects.
A team of researchers at Kyoto University has found that a deficiency in the enzyme B4GALT3 inhibits tumor growth in mice. The study shows that reduced glycosylation on T cell surfaces correlates with increased CD8+ immune cells infiltrating tumors.
Researchers found that tumour cells escape immunotherapy by losing or changing BCMA and GPRC5D targets on their surface. This understanding has led to the suggestion of periodically profiling myeloma cells throughout a patient's treatment course to adapt treatment strategies.
Researchers are testing a single target to weaken tumors and strengthen immune cells in pediatric brain tumor patients. The goal is to improve the effectiveness of CAR-T therapy, which has shown promise but also leads to exhaustion of immune cells.
Researchers discovered a new role for extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that leads to cancer cell death. Hyperactivation of ERK causes stress in cells, triggering cell death through specific proteins DR5 and NOXA.
Researchers identified a circulating tumor DNA (ctDNA) biomarker that can predict disease recurrence and response to treatment in patients with BRAF-negative melanoma. The study found that measuring ctDNA levels and variants can help tailor therapy and improve patient outcomes.
Researchers combined three highly potent cancer drugs in a single prodrug that is activated in tumor cells, resulting in improved efficacy and reduced side effects. The new approach has shown promise as a potential solution to reduce the burden on patients' bodies during cancer treatment.
Researchers at UMass Amherst have identified a small strand of microRNA called let-7 as crucial in governing the formation of cellular memories that enable T-cells to recognize and attack tumor cells. This discovery offers new insights into how vaccines work and could lead to improved cancer therapies by boosting cellular memory.
Researchers discovered that fine-tuning mitochondrial energy production reduces melanoma tumor growth and enhances immune response in mice. The study reveals that manipulating mitochondrial electron transport increases expression of immune genes and makes tumor cells more visible to killer T cells.
Researchers at the Swiss Cancer Center Léman have discovered a way to prolong the functionality of CAR-T cells, which are used against blood cancers. By inhibiting a specific metabolic mechanism, they created CAR-T cells with enhanced immune memory, capable of fighting tumour cells for longer.
New research from Cold Spring Harbor Laboratory suggests that high tumor mutation burden does not guarantee an effective immune response in patients with mismatch repair deficiency. The study found that tumors with identical mutations across all cells responded to immunotherapy, while those with subclonal mutations did not.
Researchers from Politecnico di Milano have discovered the early manifestation of therapy-induced senescence in human tumor cells. The study highlights the importance of non-invasive technologies in understanding cancer biology and paves the way for personalized treatments.
A recent study from MIT found that measuring diversity of mutations within a tumor generates more accurate predictions of treatment success than overall mutation count. This discovery could help doctors identify patients who would benefit most from checkpoint blockade inhibitors.